Martin Blankfard

Epic Sciences (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

2h-index9citations13works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(9), Cancer Cells and Metastasis(7), Single-cell and spatial transcriptomics(2), Alzheimer's disease research and treatments(1), Cancer Immunotherapy and Biomarkers(1)

Publications13 total

Abstract 1941: Development of a multiomic approach for the detection of actionable biomarkers in metastatic breast cancer
Cancer Research·2025
Abstract A001: Analytical validation of a novel multiomic metastatic breast cancer liquid biopsy test that combines ctDNA analysis with CTC HER2-ultralow and ER co-expression, as well as single-cell chromosomal instability
Clinical Cancer Research·2024
A novel liquid biopsy assay for detection of ERBB2 (HER2) amplification in circulating tumor cells (CTCs)
Journal of Circulating Biomarkers·2024· 5 citedOpen Access
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
Journal of Clinical Oncology·2024
Abstract PO5-04-04: Development of a method to detect very low levels of HER2 expression in Circulating Tumor Cells (CTCs) by liquid biopsy in patients with metastatic breast cancer
Cancer Research·2024
Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer.
Journal of Clinical Oncology·2023
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.
Journal of Clinical Oncology·2023
Abstract P5-06-03: Analyzing the results of liquid biopsy in the identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: comparison and combination of cell and cell-free platforms
Cancer Research·2023
Demonstration of the value of liquid biopsy to identify metastatic breast cancer: Comparison and combination of cell and cell-free platforms.
Journal of Clinical Oncology·2022
Improved sensitivity in identification of first recurrences of metastatic breast cancer with a combination of cell and cell-free liquid biopsy analysis.
Journal of Clinical Oncology·2022
Schlafen 11 (SLFN11), a putative predictive biomarker of platinum/PARPi response, is frequently detected on circulating tumor cells (CTCs) in advanced prostate cancer.
Journal of Clinical Oncology·2021· 4 cited
Monitoring Minimal Residual Disease in Acute Myeloid Leukemia Using Genomic or cfDNA with MyMRD®, a Targeted NGS Panel
Blood·2018
P2‐036: Novel Beta‐amyloid protein immunoassays
Alzheimer s & Dementia·2011Open Access

Frequent Co-authors

David Bourdon(9), Rick Wenstrup(7), Nilesh Dharajiya(6), Ernest T. Lam(5), Alessandra Cunsolo(5), Giuseppe Di(4), Alisa Tubbs(4), Raj Srikrishnan(4), Lee S. Schwartzberg(3), Amanda Anderson(3), Andrew G. Kunihiro(3), Tatjana Singer(3), Megan Slade(2), Ernest W.N. Lam(2), Jordan Ritchie(2), Brandon Guillory(2), Sara Tin(2), Meng Zhuo(2), Bharat Annaldas(2), Jason H. Christiansen(2)